| Quarterly Financials | Mar 2015 | Jun 2015 | Sept 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sept 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sept 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 |
Revenue  | 2,269 | 2,291 | 2,286 | 2,300 | 2,310 | 2,232 | 2,360 | 2,266 | 2,479 | 2,127 | 3,165 | 3,206 | 3,197 | 2,870 | 2,875 | 3,547 | 3,658 | 3,429 | 3,271 | 3,555 | 3,672 | 3,462 | 3,663 | 3,645 | 3,551 | 3,971 | 6,106 | 3,590 | 3,821 | 3,989 | 3,993 | 4,199 | 4,890 | 5,089 | 4,313 | 4,403 | 5,526 | 6,110 | 5,182 | 5,181 | 6,371 |
| Expenses | 1,792 | 1,807 | 1,740 | 1,768 | 1,784 | 1,763 | 1,841 | 1,907 | 2,004 | 1,909 | 2,365 | 2,404 | 2,399 | 2,249 | 2,273 | 2,738 | 2,932 | 2,864 | 3,009 | 2,947 | 3,013 | 2,724 | 2,977 | 2,867 | 2,916 | 3,092 | 2,860 | 2,895 | 3,103 | 3,251 | 3,319 | 3,301 | 4,359 | 3,650 | 3,224 | 3,403 | 3,903 | 4,124 | 3,776 | 3,882 | 4,622 |
| EBITDA | 477 | 484 | 546 | 532 | 526 | 468 | 519 | 359 | 476 | 218 | 800 | 802 | 798 | 621 | 601 | 809 | 726 | 565 | 262 | 608 | 658 | 738 | 686 | 779 | 635 | 879 | 3,246 | 695 | 718 | 738 | 673 | 898 | 532 | 1,439 | 1,089 | 1,000 | 1,623 | 1,986 | 1,407 | 1,299 | 1,749 |
| Operating Profit % | 20 % | 20 % | 23 % | 22 % | 21 % | 20 % | 21 % | 15 % | 17 % | 9 % | 25 % | 24 % | 24 % | 19 % | 20 % | 22 % | 19 % | 16 % | 7 % | 17 % | 17 % | 20 % | 17 % | 20 % | 19 % | 21 % | 22 % | 18 % | 17 % | 17 % | 16 % | 21 % | 10 % | 28 % | 24 % | 22 % | 27 % | 32 % | 26 % | 24 % | 27 % |
| Depreciation | 76 | 69 | 73 | 74 | 76 | 84 | 86 | 90 | 114 | 122 | 126 | 147 | 144 | 142 | 148 | 154 | 156 | 172 | 172 | 174 | 179 | 173 | 175 | 176 | 175 | 183 | 177 | 177 | 185 | 181 | 182 | 182 | 179 | 180 | 184 | 195 | 205 | 215 | 234 | 229 | 238 |
| Interest | 16 | 12 | 13 | 12 | 16 | 14 | 15 | 7 | 10 | 22 | 41 | 13 | 15 | 35 | 36 | 46 | 77 | 89 | 90 | 81 | 83 | 68 | 45 | 27 | 23 | 27 | 30 | 31 | 39 | 34 | 35 | 33 | 28 | 18 | 9 | 20 | 35 | 32 | 25 | 32 | 77 |
| Profit Before Tax | 426 | 519 | 545 | 537 | 498 | 441 | 435 | 324 | 412 | 154 | 712 | 722 | 724 | 570 | 535 | 672 | 606 | 394 | 122 | 457 | 522 | 588 | 524 | 617 | 526 | 777 | 3,135 | 598 | 558 | 673 | 648 | 781 | 484 | 1,328 | 1,006 | 947 | 1,550 | 1,900 | 1,271 | 1,184 | 1,672 |
| Tax | 69 | 51 | 60 | 97 | -74 | 36 | 46 | -6 | 20 | 9 | 200 | 168 | 125 | 102 | 107 | 150 | 124 | 69 | 28 | 86 | 108 | 102 | 89 | 89 | -210 | 135 | 123 | 87 | 105 | 96 | 122 | 149 | 125 | 195 | 203 | 157 | 304 | 417 | 351 | 158 | 428 |
| Net Profit | 357 | 468 | 485 | 440 | 572 | 405 | 389 | 331 | 393 | 145 | 513 | 553 | 599 | 467 | 428 | 522 | 482 | 325 | 94 | 371 | 414 | 487 | 435 | 528 | 735 | 643 | 3,012 | 511 | 453 | 576 | 526 | 631 | 358 | 1,134 | 803 | 790 | 1,246 | 1,483 | 920 | 1,026 | 1,244 |
| EPS in ₹ | 17.11 | 22.47 | 6.46 | 4.21 | 5.59 | 3.89 | 3.71 | 3.16 | 3.77 | 1.35 | 4.92 | 5.31 | 5.77 | 4.50 | 4.08 | 4.99 | 4.40 | 2.97 | 1.05 | 3.65 | 3.83 | 4.43 | 4.62 | 5.15 | 6.64 | 5.74 | 29.32 | 4.89 | 3.88 | 5.06 | 5.15 | 6.15 | 2.93 | 10.74 | 7.91 | 7.80 | 11.69 | 14.11 | 9.06 | 10.17 | 11.64 |
Zydus Life Science
974.95
-3.85
(-0.39%)
Market Cap
98,102.78 Cr
EPS
38.14
PE Ratio
21.09
Dividend Yield
1.12 %
Industry
Healthcare52 Week High
1,324.30
52 Week Low
795.00
PB Ratio
4.11
Debt to Equity
0.05
Sector
Pharmaceuticals
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from27 analysts
Company News
View All News
Zydus Lifesciences has received an Establishment Inspection Report (EIR) for its Active Pharmaceutical Ingredient (API) manufacturing facility in Ankleshwar. The U.S. Food and Drug Administration (USFDA) inspection has been closed and classified as 'No Action Indicated', which is the best possible outcome for such inspections.
Zydus Lifesciences received an EIR from the US FDA for its Ankleshwar API facility with 'No Action Indicated' status. Q4 net profit fell 1% YoY to ₹1,171 crore, below estimates. US formulation revenue grew 24% YoY to ₹3,130.7 crore. EBITDA increased 30% YoY to ₹2,126 crore, with margin expanding to 32.6%.
Zydus Lifesciences has obtained an Establishment Inspection Report (EIR) for its Active Pharmaceutical Ingredient (API) production plant in Ankleshwar. The U.S. Food and Drug Administration (USFDA) conducted an inspection of the facility, which concluded with a 'No Action Indicated' status. This outcome suggests that the inspection did not identify any significant issues requiring regulatory action.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,687.80 | #1 4,04,959.76 | 35.29 | #1 49,887.20 | 12.06 | #1 9,648 | -18.99 | 46.16 | |
6,667.00 | 1,76,987.90 | 81.46 | 8,184.00 | 0.89 | 1,600 | 23.05 | 60.61 | |
1,505.20 | 1,21,562.20 | 23.01 | 26,520.70 | 14.17 | 4,155 | 30.28 | 53.87 | |
1,362.50 | 1,13,694.54 | 20.11 | 28,905.40 | 12.36 | 5,578 | 21.14 | 84.56 | |
3,252.50 | 1,10,079.38 | 57.23 | 10,785.70 | 11.59 | 1,656 | 10.91 | 56.97 | |
2,381.30 | 98,247.32 | 49.58 | 10,615.60 | 19.57 | 1,942 | -10.91 | 43.09 | |
974.95 | #7 98,102.78 | #3 21.09 | #6 19,831.50 | #5 13.82 | #4 3,831 | #7 -0.19 | 71.52 | |
1,999.60 | 91,289.93 | 28.14 | 20,141.50 | #1 19.94 | 1,936 | #1 112.49 | 49.72 | |
31,515.00 | 66,967.18 | 47.29 | 6,097.20 | 10.80 | 1,201 | 27.83 | 59.42 | |
1,150.20 | 66,803.80 | #1 19.42 | 29,559.20 | 17.55 | 3,169 | -0.50 | 44.60 |
Forecast
Actual
Growth Rate
Revenue Growth
13.82 %
Net Income Growth
91.39 %
Cash Flow Change
20.05 %
ROE
70.50 %
ROCE
52.01 %
EBITDA Margin (Avg.)
23.08 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Total Assets | 9,047 | 10,551 | 15,221 | 18,065 | 23,483 | 23,687 | 23,885 | 27,795 | 25,756 | 29,281 |
| Fixed Assets | 3,352 | 3,748 | 5,755 | 6,483 | 12,164 | 12,231 | 12,133 | 12,189 | 11,521 | 12,369 |
| Current Assets | 4,227 | 4,280 | 6,022 | 8,230 | 8,498 | 8,715 | 8,716 | 12,095 | 10,008 | 11,420 |
| Capital Work in Progress | 798 | 951 | 1,543 | 1,527 | 837 | 742 | 783 | 726 | 1,201 | 2,423 |
| Investments | 121 | 416 | 435 | 746 | 674 | 765 | 830 | 3,288 | 1,547 | 1,221 |
| Other Assets | 4,776 | 5,436 | 7,488 | 9,310 | 9,809 | 9,950 | 10,139 | 11,593 | 11,488 | 13,269 |
| Total Liabilities | 9,047 | 10,551 | 15,221 | 18,065 | 23,483 | 23,687 | 23,885 | 27,795 | 25,756 | 29,281 |
| Current Liabilities | 3,285 | 3,461 | 5,306 | 6,083 | 7,343 | 8,269 | 7,861 | 7,827 | 5,527 | 5,340 |
| Non Current Liabilities | 1,342 | 1,255 | 2,799 | 3,047 | 4,461 | 3,707 | 1,094 | 915 | 541 | 1,840 |
| Total Equity | 4,421 | 5,835 | 7,116 | 8,936 | 11,679 | 11,710 | 14,930 | 19,054 | 19,688 | 22,102 |
| Reserve & Surplus | 4,149 | 5,597 | 6,858 | 8,642 | 10,284 | 10,273 | 12,890 | 16,897 | 17,415 | 19,729 |
| Share Capital | 102 | 102 | 102 | 102 | 102 | 102 | 102 | 102 | 101 | 101 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Net Cash Flow | 178 | 99 | 756 | -3 | -811 | 399 | -91 | 219 | -170 | -75 |
| Investing Activities | -465 | -860 | -2,872 | -974 | -3,977 | -1,004 | -837 | -1,018 | 1,542 | -1,492 |
| Operating Activities | 994 | 1,894 | 1,312 | 919 | 1,282 | 2,932 | 3,294 | 2,105 | 2,689 | 3,228 |
| Financing Activities | -351 | -935 | 2,316 | 52 | 1,885 | -1,528 | -2,548 | -868 | -4,400 | -1,810 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 |
| Promoter | 74.88 % | 74.88 % | 74.88 % | 74.88 % | 74.88 % | 74.88 % | 74.98 % | 74.98 % | 74.98 % | 74.98 % | 74.98 % | 74.98 % | 74.98 % | 74.98 % | 74.98 % | 74.98 % | 74.99 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 5.72 % | 5.59 % | 7.52 % | 7.53 % | 7.32 % |
| DIIs | 11.11 % | 10.43 % | 11.22 % | 11.78 % | 12.78 % | 11.92 % | 12.94 % | 13.69 % | 13.60 % | 13.23 % | 13.09 % | 12.79 % | 12.63 % | 12.64 % | 10.65 % | 10.65 % | 11.01 % |
| Government | 0.19 % | 0.07 % | 0.07 % | 0.07 % | 0.08 % | 0.08 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 6.16 % | 7.31 % | 7.38 % | 7.40 % | 7.81 % | 8.02 % | 7.60 % | 7.04 % | 6.42 % | 5.97 % | 5.67 % | 5.60 % | 5.29 % | 5.37 % | 5.48 % | 5.47 % | 5.41 % |
| Others | 7.66 % | 7.32 % | 6.44 % | 5.87 % | 4.46 % | 5.11 % | 4.48 % | 4.29 % | 5.00 % | 5.82 % | 6.26 % | 6.63 % | 1.38 % | 1.43 % | 1.37 % | 1.36 % | 1.28 % |
| No of Share Holders | 0 | 2,23,384 | 3,31,155 | 3,51,595 | 3,70,931 | 4,08,017 | 4,55,624 | 4,08,231 | 3,70,396 | 3,11,764 | 2,97,953 | 3,06,495 | 2,94,324 | 3,36,309 | 3,70,863 | 3,65,356 | 3,71,619 |
Dividend History
Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 3.2 | 3.5 | 3.5 | 3.5 | 3.5 | 2.5 | 6 | 3 | 0.00 |
| Dividend Yield (%) | 0.00 | 0.85 | 1.01 | 1.31 | 0.79 | 1 | 0.51 | 0.6 | 0.34 | 0.00 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 12 Aug 2025 |  Annual General Meeting | NA | 12 Aug 2025 | 911.40 | 974.95 |
| 25 Jul 2025 |  Dividend | ₹ 11.00 /share | 25 Jul 2025 | 902.70 | 974.95 |
| 20 May 2025 |  Quarterly Result Announcement | NA | 20 May 2025 | 873.70 | 911.40 |
| 05 Feb 2025 | Quarterly Result Announcement | NA | 05 Feb 2025 | 995.50 | 974.00 |
| 12 Nov 2024 | Quarterly Result Announcement | NA | 12 Nov 2024 | 1,002.20 | 968.55 |
| 09 Aug 2024 | Annual General Meeting | NA | 09 Aug 2024 | 1,009.00 | 1,279.40 |
| 26 Jul 2024 | Dividend | ₹ 3.00 /share | 26 Jul 2024 | 1,009.00 | 1,205.80 |
| 28 Jul 2023 | Dividend | ₹ 6.00 /share | 28 Jul 2023 | 518.80 | 649.50 |
| 29 Jul 2022 | Dividend | ₹ 2.50 /share | 28 Jul 2022 | 338.75 | 349.60 |
| 30 Jul 2021 | Dividend | ₹ 3.50 /share | 28 Jul 2021 | 628.10 | 571.90 |
Announcements
Announcement under Regulation 30 (LODR)-Press Release / Media Release
3 days ago
3 days agoAnnouncement under Regulation 30 (LODR)-Press Release / Media Release4 days ago
4 days agoESG Rating7 days ago
7 days agoAnnouncement under Regulation 30 (LODR)-AcquisitionJun 03, 2025
Jun 03, 2025Definitive Exclusive Licensing Agreement With Agenus Inc. USAJun 03, 2025
Jun 03, 2025Announcement under Regulation 30 (LODR)-AcquisitionJun 03, 2025
Jun 03, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseJun 02, 2025
Jun 02, 2025Announcement under Regulation 30 (LODR)-AcquisitionMay 28, 2025
May 28, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 28, 2025
May 28, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 28, 2025
May 28, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 27, 2025
May 27, 2025Announcement under Regulation 30 (LODR)-Earnings Call TranscriptMay 27, 2025
May 27, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 23, 2025
May 23, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 21, 2025
May 21, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 20, 2025
May 20, 2025Change In Authority To Determine Materiality Of An EventMay 20, 2025
May 20, 2025Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 20, 2025
May 20, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 20, 2025
May 20, 2025Announcement under Regulation 30 (LODR)-Investor PresentationMay 20, 2025
May 20, 2025Announcement under Regulation 30 (LODR)-Change in ManagementMay 20, 2025
May 20, 2025Record Date For Dividend Is July 25 2025May 20, 2025
May 20, 2025Announcement under Regulation 30 (LODR)-Change in ManagementMay 20, 2025
May 20, 2025Announcement under Regulation 30 (LODR)-Change in DirectorateMay 20, 2025
May 20, 2025Corporate Action-Board approves DividendMay 20, 2025
May 20, 2025Audited Financial Results For The Quarter And Year Ended March 31 2025May 20, 2025
May 20, 2025Board Meeting Outcome for Audited Financial Results For The Quarter And Year Ended March 31 2025May 20, 2025
May 20, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 16, 2025
May 16, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 14, 2025
May 14, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationMay 13, 2025
May 13, 2025Board Meeting Intimation for Approval Of Audited Financial Results For The Quarter / Year Ended On March 31 2025.May 09, 2025
May 09, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 08, 2025
May 08, 2025Announcement under Regulation 30 (LODR)-Change in ManagementApr 30, 2025
Apr 30, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 30, 2025
Apr 30, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 26, 2025
Apr 26, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 25, 2025
Apr 25, 2025Announcement under Regulation 30 (LODR)-Updates on AcquisitionApr 25, 2025
Apr 25, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 17, 2025
Apr 17, 2025Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015.Apr 17, 2025
Apr 17, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 17, 2025
Apr 17, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 16, 2025
Apr 16, 2025Rumour verification - Regulation 30(11)Apr 16, 2025
Apr 16, 2025Clarification/Confirmation On News Item Appearing In "Www.Cnbctv18.Com"Apr 16, 2025
Apr 16, 2025Clarification sought from Zydus Lifesciences LtdApr 16, 2025
Apr 16, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 11, 2025
Apr 11, 2025Incorporation Of A Wholly Owned Subsidiary In FranceApr 11, 2025
Apr 11, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 09, 2025
Apr 09, 2025Announcement under Regulation 30 (LODR)-Updates on AcquisitionMar 28, 2025
Mar 28, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMar 28, 2025
Mar 28, 2025Closure of Trading WindowMar 25, 2025
Mar 25, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMar 18, 2025
Mar 18, 2025Technical Indicators
RSI(14)
Neutral 71.52
ATR(14)
Less Volatile 19.01
STOCH(9,6)
Overbought 86.80
STOCH RSI(14)
Overbought 83.65
MACD(12,26)
Bullish 4.27
ADX(14)
Weak Trend 22.88
UO(9)
Bearish 63.71
ROC(12)
Uptrend And Accelerating 5.33
WillR(14)
Neutral -25.05
Mutual Fund Holdings
| Funding House | No of Shares | Current Holding % | 1M Change % | 3M Change % | Month | |
|---|---|---|---|---|---|---|
 Kotak Equity Arbitrage Fund Direct-Growth | 408600 | 0.06% | -0.10% | -0.09% | May 2025 | |
| Kotak Bluechip Fund Direct-Growth | 284489 | 0.26% | -0.58% | -0.61% | May 2025 | |
 ICICI Prudential Innovation Fund Direct - Growth | 1076714 | 1.47% | 0.48% | 0.04% | May 2025 | |
 Parag Parikh Flexi Cap Fund Direct-Growth | 14258435 | 1.28% | 0.02% | 0.04% | May 2025 | |
 Baroda BNP Paribas Midcap Fund Direct-Growth | 250000 | 1.09% | 1.09% | 0.46% | May 2025 | |
 Tata Arbitrage Fund Direct - Growth | 108000 | 0.07% | -0.16% | -0.14% | May 2025 | |
 HDFC Arbitrage Fund Wholesale Direct-Growth | 39600 | 0.02% | -0.08% | -0.05% | May 2025 | |
 DSP Quant Fund Direct - Growth | 164439 | 1.69% | 1.69% | 1.69% | May 2025 | |
 Sundaram Multi Asset Allocation Fund Direct - Growth | 160000 | 0.57% | 0.57% | 0.57% | May 2025 | |
 Invesco India Arbitrage Fund Direct-Growth | 293400 | 0.12% | -0.07% | -0.05% | May 2025 | |
 Nippon India Arbitrage Fund Direct-Growth | 540900 | 0.35% | -0.07% | 0.19% | May 2025 | |
 Axis India Manufacturing Fund Direct-Growth | 359031 | 0.60% | -0.19% | -0.25% | May 2025 | |
 Mirae Asset Healthcare Fund Direct - Growth | 21721 | 0.08% | -0.39% | -0.40% | May 2025 | |
| Baroda BNP Paribas Value Fund Direct - Growth | 115000 | 0.81% | 0.81% | 0.81% | May 2025 | |
 LIC MF ELSS Tax Saver Direct - Growth | 0 | 0.00% | -0.88% | -0.88% | May 2025 | |
| Nippon India Vision Direct-Growth | 0 | 0.00% | -0.16% | -0.16% | May 2025 | |
 Edelweiss Arbitrage Fund Direct-Growth | 73800 | 0.05% | -0.05% | -0.01% | May 2025 | |
| ICICI Prudential Equity Arbitrage Direct-Growth | 144000 | 0.05% | -0.03% | 0.01% | May 2025 | |
 UTI Arbitrage Fund Direct-Growth | 153000 | 0.19% | -0.09% | 0.07% | May 2025 | |
| ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct - Growth | 2375809 | 4.01% | 0.13% | 0.91% | May 2025 | |
| Edelweiss Large Cap Fund Direct -Growth | 55300 | 0.40% | 0.40% | 0.40% | May 2025 | |
 SBI Arbitrage Opportunities Fund Direct-Growth | 322200 | 0.09% | -0.01% | 0.04% | May 2025 | |
| Sundaram Aggressive Hybrid Fund Direct-Growth | 436510 | 0.66% | -0.06% | -0.10% | May 2025 | |
 Quant Arbitrage Fund Direct - Growth | 24300 | 2.20% | 2.20% | 2.20% | May 2025 | |
 Union Arbitrage Fund Direct - Growth | 0 | 0.00% | -0.64% | 0.00% | May 2025 |
About Zydus Life Science
Zydus Lifesciences Limited is an Indian global life sciences company that discovers, develops, manufactures, and markets healthcare therapies. Its product portfolio includes active pharmaceutical ingredients, human formulations, animal health products, and wellness products. The company operates in pharmaceuticals, covering human and veterinary formulations, bulk drugs, diagnostics, herbal products, skin care, and over-the-counter products. Zydus has a global presence, marketing products in the United States, India, Europe, and emerging markets. Key products include Lipaglyn, Bilypsa, Ujvira, Exemptia, Vivitra, and Bryxta, covering areas such as oncology, autoimmune diseases, nephrology, and infectious illnesses. The company has manufacturing facilities in various Indian states and has made several strategic acquisitions and partnerships to expand its product range and market presence.
Listing Date
27 Apr, 2000(25 Years,
-13 days)
Website
Chairperson NamePankaj R Patel
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
